What tirzepatide treats — and what it actually does to appetite

The biggest misconception: tirzepatide is not simply a 'hunger switch'

The most common misreading of tirzepatide is that it just switches off appetite. That framing is appealing but incomplete, and it matters because it leads people to expect a passive experience when the reality asks more of you.

Tirzepatide binds to receptors for two gut hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both are released naturally after eating. GLP-1 slows the rate at which food leaves the stomach and signals fullness to the brain; GIP amplifies the insulin response and appears to influence how the body stores fat. Together they reduce appetite, but they also reshape the physical experience of eating. Gastric emptying slows, so a small meal may feel genuinely filling for two or three hours. That is useful, but it also means eating too much in one sitting can be uncomfortable rather than just unsatisfying.

The practical consequence is that diet still matters on tirzepatide. The medicine adjusts the signals; you still make the choices. Understanding what to eat while taking tirzepatide is not a bonus topic, it shapes how well treatment works and how tolerable the early weeks feel. Nausea is far more likely if you eat large, fatty or heavily processed meals, particularly around a dose increase. Our clinical team hears this from patients regularly: the people who adjust their eating pattern early find the first month far easier than those who wait for the medicine to 'do the work'.

The two UK-licensed indications explained plainly

Tirzepatide holds two distinct UK licences. The first is for weight management, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or more, or 27 or more in the presence of at least one weight-related condition. Qualifying conditions include type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, and cardiovascular disease. Lower BMI thresholds can apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

The second licence is for type 2 diabetes in adults, where tirzepatide improves blood sugar control, and you can read more about the full range of conditions tirzepatide is used to treat to understand how the two licences sit alongside each other. This is the indication most GPs have known longest, because tirzepatide entered the UK market through diabetes care before the weight-management licence was granted.

These two licences occasionally overlap: someone with type 2 diabetes and a BMI above 30 may qualify under either. That overlap requires prescriber judgement, the diabetes licence follows a different dosing pathway and interacts with other glucose-lowering medicines differently. If you are currently prescribed tirzepatide for diabetes and are wondering about its role in weight management, your diabetes team or a specialist prescriber is the right person to discuss that with rather than switching independently.

The NICE appraisal of tirzepatide (TA1026) sets out the specific eligibility criteria for NHS use in weight management, criteria that are stricter than the licence itself, because NHS access is phased by BMI and comorbidity count.

What the trial evidence showed about tirzepatide's effect on weight

The SURMOUNT-1 trial (which randomised 2,539 adults with obesity, without diabetes) reported average body-weight reductions of around 20 to 21 percent at the 15mg dose over 72 weeks, alongside lifestyle changes. These are the figures cited in NICE's appraisal and in the published paper in the New England Journal of Medicine. They are averages from a clinical trial, not a personal prediction; individual results depend on the dose reached, adherence, diet, activity, and underlying health.

For context on the range of licensed weight-loss treatments available in the UK, the position tirzepatide occupies is as the only dual-agonist option; semaglutide (Wegovy) acts on one receptor pathway and produced around 15 percent average loss in its pivotal trial.

Food choices during treatment are not just background advice. Protein intake helps preserve muscle alongside fat loss. Adequate hydration reduces the risk of constipation, which is one of the more persistent side effects. Smaller, more frequent meals sit more comfortably with slowed gastric emptying. Our guidance on what to eat on Mounjaro covers the practical layer that trial data does not capture, and knowing which foods work well with tirzepatide and which are best avoided is a question worth preparing an answer to before your first pen arrives, ideally before the school-run rush of week one when you are already tired.

When to get medical help and how to report concerns

The most important safety facts for anyone starting tirzepatide relate to symptoms that go beyond ordinary nausea. Severe or persistent stomach pain, particularly if it radiates through to the back, needs prompt medical attention, it can signal acute pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update as an infrequent but serious risk associated with GLP-1 medicines. Gallbladder symptoms (upper-right abdominal pain, fever, jaundice) also warrant urgent review.

Common side effects (nausea, loose stools, constipation, burping, fatigue) are expected in early treatment and around dose increases. They typically settle within days to two weeks. Injection-site reactions are usually mild.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. Women taking the oral contraceptive pill should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because slowed gastric emptying may reduce pill absorption. Our guidance on tirzepatide and food also covers how meal timing and composition interact with these absorption considerations.

Any suspected side effect can be reported through the MHRA Yellow Card scheme, that applies to patients and carers as well as healthcare professionals. If you have questions about how treatment is going, our aftercare team is available seven days a week.